Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New 6-Month TB drug cocktail could replace Year-Long ordeal

NCT ID NCT07486024

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 17, 2026 · Updated 2 times

Summary

This study tests a new 6-month treatment called BPaLM for people with multidrug-resistant tuberculosis (MDR-TB). The goal is to see if it works as well as the current 18+ month regimen. About 55 adults in France will receive the shorter treatment, and their outcomes will be compared to past patients who had standard care. If effective, this could greatly reduce treatment burden and improve quality of life for MDR-TB patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BPaLM regimen (bedaquiline, pretomanid, linezolid, moxifloxacin)
What this could lead to
If successful, this could offer a much shorter, more tolerable treatment for multidrug-resistant tuberculosis, replacing the current long and difficult regimen.
What could go wrong
This is a small, non-randomized trial comparing to historical data, so results may not be conclusive. The regimen still requires careful monitoring for side effects like nerve damage or heart issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 55 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2026

Expected to finish

Feb 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria 1. Is 18 years old or more 2. Is affected by bacteriologically- or molecularly-confirmed tuberculosis, due to strains of M. tuberculosis resistant to rifampicin (with or without resistance to isoniazid) according to a rapid molecular test 3. Is willing and able to give informed consent to be enrolled in the research project (signed or witnessed consent if the patient is illiterate) 4. Patients seen in consultation or hospitalized in one of the centers involved for rifampicin-resistant TB, with screening results available and compatible within 14 days following consent signature; 5. Is willing to use effective\* contraception: women with childbearing potential\*\* must agree to use effective contraception, unless their partner has had a vasectomy, for the duration of study treatment and up to 6 months after the end of study treatment; men who have not had a vasectomy must agree to use effective contraception for the duration of study treatment and up to 3 months after the end of study treatment; * The following contraception methods are considered effective, according to local regulation (CTFG recommendations, March 2024): 1. Combined hormonal contraception (oestrogen + progestin) 2. Progestin-only hormonal contraception 3. Intrauterine device (IUD) 4. Intrauterine hormone-releasing system (IUS) 5. Bilateral tubal occlusion 6. Vasectomised partner * A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. 6. Is affiliated to a social security system (as beneficiary) or has state medical aid (AME) or has an ongoing demand for AMEor has an ongoing demand for an emergency medical care (dispositif de soins d'urgence, as applicable for tuberculosis) Exclusion criteria : 1. Is unable to take oral drugs 2. Has known allergies, hypersensitivity or intolerance or any other medical condition and contra indications to any drug of the regimen 3. Unwilling to comply to study procedures, at the clinician appreciation 4. Has proven or likely resistance to bedaquiline, clofazimine, linezolid, pretomanid or moxifloxacine, or has had exposure (for 30 days or more) in past five years to bedaquiline, clofazimine, delamanid, linezolid, or pretomanid 5. Is taking or needs to take contraindicated medications in association with investigational medicinal products 6. Has ≥500 msec QTcF interval on any ECG taken at screening or baseline visits, or has any cardiac risk factor for severe arrhythmia 7. Has severe extrapulmonary TB, including meningo-encephalitis, brain abscess, osteo-arthritis, osteomyelitis 8. Is concurrently participating in another trial of any medicinal product 9. Is already on a MDR/RR-TB treatment regimen since 4 weeks or more, and has no need to change the treatment regimen (i.e. adverse events, treatment failure) 10. Has significant and uncorrectable lab abnormalities at baseline: haemoglobin ≤7.9 g/dL, platelet count \<75 000/mm3; absolute neutrophil count \<1 000/ mm3; potassium \<3.0 mEq/L; serum creatinine \>3 x upper level of normality (ULN); alanine aminotransferase (ALT) ≥3 x ULN 11. Has peripheral neuropathy of grade 3 or 4 (CTCAE scale) 12. Has any other condition (social or medical) which, in the opinion of the site investigator, would make the study participant unsafe 13. Is known to be pregnant or is unwilling or unable to stop breastfeeding an infant 14. Individuals permanently legally incompetent adults, under judicial or administrative protection and vulnerable persons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antibiotic resistance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Amiens

    RECRUITING

    Amiens, France

  • CHU Bichat - Claude-Bernard

    RECRUITING

    Paris, 75018, France

  • CHU Rennes

    RECRUITING

    Rennes, France

  • CHU Toulouse - Hôpital Purpan

    RECRUITING

    Toulouse, 31059, France

  • Pitié-Salpêtrière Hospital - infectious and tropical diseases

    NOT_YET_RECRUITING

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.